Integrin alpha V beta 1

Integrin alpha V beta 1 분자 정보

영어 이름Integrin alpha-V/beta-1시판 약물 수0
임상 약물 수5표적 별명
최고 연구 개발 단계Phase 2 Clinical
영어 이름Integrin alpha-V/beta-1
표적 별명
시판 약물 수0
임상 약물 수5
최고 연구 개발 단계Phase 2 Clinical

Integrin alpha V beta 1분자 배경

Integrin alpha V beta 1 (αVβ1) is a widely expressed adhesion receptor formed by the non-covalent association of the αV and β1 (CD29) subunits. Its activity is regulated by a conformational shift from a folded, low-affinity state to an extended, high-affinity state, a process triggered by divalent cations and intracellular signaling. As a canonical RGD-binding integrin, it interacts with ligands including vitronectin, fibronectin, and osteopontin. This interaction is central to its role in mediating cell migration, where its modest binding affinity enables the cyclic attachment and detachment necessary for cell movement. Furthermore, αVβ1 is implicated in cellular differentiation and is co-opted by pathogens, such as foot-and-mouth disease virus, for host cell entry.

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
IDL-2965IDL-2965Phase 2 ClinicalIndalo Therapeutics IncIdiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
상세
BexotegrastPLN-74809Phase 2 ClinicalPliant Therapeutics IncCholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Respiratory Distress Syndrome, Adult
상세
PLN-1474PLN-1474Phase 1 ClinicalPliant Therapeutics IncLiver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
상세
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics IncSolid tumours
상세
Cu-64-LLP2ACu-64-LLP2A; 64Cu-LLP2APhase 1 ClinicalUniversity Of PittsburghAnemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Waldenstrom Macroglobulinemia
상세

제품 리뷰

  • 분자 정보
  • 제품 목록
  • 제품 리뷰
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호